Loading
CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.
CT3001 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Crossignal Therapeutics, Inc., in colorectal cancer, pancreatic ductal adenocarcinoma. Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording.
1.CT3001 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CT3001" OR ABSTRACT:"CT3001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CT3001, not a curated reading list.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.